Insights into Digital Therapeutics Space and Associated Evidence Thresholds : Episode 1

Insights into Digital Therapeutics Space and Associated Evidence Thresholds

March 28, 2024

Opinion

Video

Diana Brixner, PhD, FAMCP, of the University of Utah opens a discussion surrounding digital therapeutics.

Now Viewing

EP: 1.Insights into Digital Therapeutics Space and Associated Evidence Thresholds

EP: 2.Evidence Thresholds for Prescription vs Non-Prescription Digital Therapeutics

EP: 3.Industry Collaboration in Shaping Digital Therapeutics Standards

EP: 4.Payer Challenges in Evaluating Digital Therapeutics

EP: 5.Cost-Effectiveness Metrics Payers Seek for Digital Therapeutics

EP: 6.Developing Reimbursement Models for Digital Therapeutics

EP: 7.Adoption Lessons For Payers

EP: 8.Gaps in Evidence Generation for Digital Therapeutics

EP: 9.Overcoming Implementation Barriers for Digital Therapeutics Adoption

Related Content

Value-Based Decision-Making in Metastatic Breast Cancer

Ian E. Krop, MD, PhD;Debra Patt, MD, PhD, MBA

September 16th 2021

Article

In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of the discussion.